Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.50 |
| ▸ | IGF1R | P08069 | 4/20 | 0.50 |
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | FLT4 | P35916 | 3/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 3/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MPI | P34949 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494347 | 0.80 | KMT2A (0.61) | KDRIGF1REGFRFLT4KMT2A | |
| SCHEMBL6493932 | 0.77 | ADRA2C (0.55) | KDRIGF1REGFRFLT4FLT1 | |
| SCHEMBL6482988 | 0.77 | CA12 (0.58) | KDRIGF1REGFRFLT4KMT2A | |
| SCHEMBL6484144 | 0.77 | HDAC8 (0.47) | KDRIGF1REGFRFLT4KMT2A | |
| SCHEMBL6482039 | 0.76 | LOXL2 (0.42) | KDRIGF1REGFRFLT4HTR1A | |
| SCHEMBL6492152 | 0.75 | KMT2A (0.45) | KDRIGF1REGFRFLT4HTR1A | |
| SCHEMBL6483245 | 0.75 | KDM4E (0.40) | KDRIGF1REGFRFLT4KMT2A | |
| SCHEMBL17177678 | 0.75 | HTR1A (0.50) | KDRHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL6494857 | 0.74 | HDAC8 (0.47) | KDRIGF1REGFRFLT4KMT2A | |
| SCHEMBL6484427 | 0.74 | HDAC8 (0.57) | KMT2AKDM4EALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | claimed |
| US-6800656-B2 | Tricyclic compounds and method of treating herpes virus | WARNER LAMBERT COMPANY | 2004-10-05 | — | — | US | claimed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | claimed |
| EP-1248777-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | claimed |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | disclosed |
| US-6800656-B2 | Tricyclic compounds and method of treating herpes virus | WARNER LAMBERT COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | disclosed |
| EP-1248777-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | HDAC8, ZC3HAV1, ZCCHC8 | KDR 1823/4885IGF1R 3806/4885EGFR 1980/4885 |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | HDAC8, CDK8, ZC3HAV1 | KDR 1651/4885IGF1R 2250/4885EGFR 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.